Sleep Duration and "on" Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release.

Parkinsons Dis · 2011 · PMC3109339 · PMID 21687750

Europe PMC DOI

hedged sentence

0.2041

closest p · 4.1× alpha

0.2041

boldest claim

The sentences

a nonsignificant trendP = 0.2041not close (p > 0.1)

At night, sleep duration increased in both groups from baseline to week 24 LOCF, and there was a nonsignificant trend for a greater increase in the ropinirole prolonged release group (adjusted mean treatment difference [AMTD], 0.16; 95% confidence interval [CI]: −0.09, 0.41; P = 0.2041).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.